04
Sep

Edison Pharmaceuticals’ in-development rare disease treatment missed its primary endpoint in a mid-stage trial, denting the company’s plans for an expansive take on CNS R&D.

…read more

Source: Edison’s orphan drug misses the mark in Phase II

    

0 No comments